Riskpilot← Back to searchSign inGet full accessIFOCUS ØYEKLINIKK STAVANGER AS
ASActiveOrg 925714801Verksgata 2, 4013 StavangerMedical specialists activities · NACE 8622Est. 20202 employees
Revenue 2025
NOK 11,9M
+16% vs 2024
EBITDA margin
9.2%
+109% vs 2024
Equity ratio
44.8%
Financial strength
Net profit 2025
NOK 606K
+218% vs 2024
| Revenue | NOK 11,9M | +16% |
| EBITDA | NOK 1,1M | +109% |
| Net profit | NOK 606K | +218% |
| Total assets | NOK 3,5M | +31% |
| Equity | NOK 1,6M | +73% |
| Employees | 2 | — |
Legal name
IFOCUS ØYEKLINIKK STAVANGER AS
Org number
925714801
Legal form
Aksjeselskap
NACE code
8622 · Medical specialists activities
Founded
29. september 2020
Share capital
NOK 1 530 000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Daglig leder eller styrets leder hver for seg.
Company purpose
Legevirksomhet og annen tjenesteytende virksomhet og handel, samt erverve og drive eiendommer, samt hva herved står i forbindelse, herunder å delta i andre foretagender som driver tilsvarende virksomhet.
Address
Verksgata 2, 4013 Stavanger
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 6 587 | 10 296 | 11 896 |
| Staff expenses | −0 | −0 | −988 | −1 186 | −1 746 |
| EBITDA | −61 | −43 | −1 487 | 522 | 1 093 |
| Depreciation & amort. | −0 | −0 | −149 | −232 | −262 |
| EBIT | −61 | −43 | −1 636 | 291 | 830 |
| Net financials | 0 | 0 | −62 | −45 | −54 |
| Profit before tax | −61 | −43 | −1 698 | 245 | 777 |
| Tax | −13 | −11 | −375 | 55 | 171 |
| Net profit | −48 | −32 | −1 323 | 191 | 606 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 85 | 1 730 | 3 279 | 2 710 | 3 539 |
| Equity | 22 | 1 529 | 728 | 919 | 1 586 |
| Long-term debt | 0 | 0 | 0 | 502 | 0 |
| Short-term debt | 63 | 201 | 2 551 | 1 289 | 1 576 |
| Total debt | 63 | 201 | 2 551 | 1 791 | 1 952 |
EBITDA margin
9.2%
This company
15.8%
Market median
-42% vs market
20212025
Equity ratio
44.8%
This company
38.2%
Market median
+17% vs market
20212025
Return on equity
38.2%
This company
18.4%
Market median
+108% vs market
20212025
Net profit margin
5.1%
This company
8.1%
Market median
-37% vs market
20212025
Asset turnover
3.36×
This company
1.12×
Market median
+200% vs market
20212025
Debt / equity
1.23×
This company
0.62×
Market median
-98% vs market
20212025
- Annual report 2025Filed via Brønnøysundsregistrene · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
AL Chief Executive Officer | Chief Executive Officer | 2025 |
IU Chief Executive Officer | Chief Executive Officer | 2021 |
| Former (1) | ||
EH Accountant | Accountant | 2020 – 2023 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2020 | |
| Board of Directors | 2020 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Vismed Holding As
IFOCUS ØYEKLINIKK STAVANGER AS Board members of IFOCUS ØYEKLINIKK STAVANGER AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Elisabeth Hansen | Accountant | 0 companies |
| Anne Lise Fossum | Chief Executive Officer | 0 companies |
| Inger Utvik | Chief Executive Officer | 0 companies |
| Kjell Gunnar Gundersen | Chairman | 0 companies |
| Morten Pensgård Gundersen | Board of Directors | 0 companies |